BCAX (STOCKS)
Bicara Therapeutics Inc. Common Stock
$22.160800
+1.040800 (+4.93%)
Prev close: $21.120000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Claire Mazumdar
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,448.13M
- Employees
- 103
- P/E (TTM)
- -8.37
- P/B (TTM)
- 2.98
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
10
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.68 | $-0.68 | +0.0045 | +0.66% |
|
Sep 2025 (Q3)
|
$-0.67 | $-0.56 | -0.1098 | -19.60% |
|
Jun 2025 (Q2)
|
$-0.50 | $-0.58 | +0.0799 | +13.78% |
|
Mar 2025 (Q1)
|
$-0.68 | $-0.42 | -0.2568 | -60.68% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $17.87M |
| Operating Expenses | $155.60M |
| Operating Income/Loss | -$155.60M |
| Income/Loss From Continuing Operations After Tax | -$137.95M |
| Income/Loss From Continuing Operations Before Tax | -$137.73M |
| Income Tax Expense/Benefit | $217.00K |
| Income Tax Expense/Benefit, Current | $217.00K |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$137.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$137.95M |
| Net Income/Loss Available To Common Stockholders, Basic | -$137.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.52 |
| Diluted Earnings Per Share | -$2.52 |
| Basic Average Shares | 54,676,896,000 |
| Diluted Average Shares | 54,676,896,000 |
| Assets | $430.99M |
| Current Assets | $422.05M |
| Cash | $414.80M |
| Other Current Assets | $7.25M |
| Noncurrent Assets | $8.94M |
| Fixed Assets | $330.00K |
| Other Non-current Assets | $8.61M |
| Liabilities | $29.54M |
| Current Liabilities | $28.95M |
| Wages | $5.04M |
| Other Current Liabilities | $23.91M |
| Noncurrent Liabilities | $593.00K |
| Equity | $401.45M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $401.45M |
| Liabilities And Equity | $430.99M |
| Net Cash Flow From Operating Activities | -$106.83M |
| Net Cash Flow From Operating Activities, Continuing | -$106.83M |
| Net Cash Flow From Investing Activities | -$318.45M |
| Net Cash Flow From Investing Activities, Continuing | -$318.45M |
| Net Cash Flow From Financing Activities | $32.26M |
| Net Cash Flow From Financing Activities, Continuing | $32.26M |
| Net Cash Flow | -$393.03M |
| Net Cash Flow, Continuing | -$393.03M |
| Comprehensive Income/Loss | -$137.71M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$137.71M |
| Other Comprehensive Income/Loss | -$137.71M |
| Other Comprehensive Income/Loss Attributable To Parent | $243.00K |